I Know First Review: CELG New Partnership

I Know First Review

I Know First Review

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation

I Know First also wrote a Seeking Alpha article about Celgene on Nov 23rd, 2015. in accordance to the I Know First algorithmic signal. Claiming that improving the lives of patients worldwide will improve the lives of patient investors showing off their sales for 3Q increase of 12% to $1,453mn. Since that time, the stock price has increased 8%.

The big news for Celgene in 2015 was the buy of Receptos. With over $7 billion in cash, it wouldn’t be surprising to see the big biotech make another buy next year.But the company will most likely partnerships will play an important role for Celgene in 2016.

Celgene’s deal with Juno Therapeutics (NASDAQ:JUNO) it is the  most important current partnership. Juno is a leader in T cell therapeutics for treatment of various types of cancer. Celgene paid $150 million upfront, plus bought 10% of Juno’s stock in exchange for an option to sell several of Juno’s drug candidates.

CELG stock climbed more than 9% today, pushing over the 200-day moving average for the first time in six weeks.

The company is predicting an earnings per share growth of 19.52% in the coming year.Celgene Corporation had an earnings per share growth of 23.60% in the last 5 years. Currently the ROI is 26.50% and its debt to equity ratio is 2.88. CELG has a market cap total of $ 95904.3, a gross margin of 95.20% while the profit margin is 18.90% and the ROI is 16.30%


The Algorithmic signal for CELG in the next year is 63.48 which has a very high predictability of 0.34. For more on how to read the algorithmic predictions click HERE.